EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Meet the Contributors →

Latest News

  1. 1.

    With “Inflection Year” Ahead, Ovid Adds Novartis’s Tardio to C-Suite | New York

  2. 2.

    Underdog Launches With $4M to Target “Toxic” Form of Cholesterol | San Francisco

  3. 3.

    Alkermes Eyes Brain Disorders and Beyond With $100M Deal for Rodin | Boston

  4. 4.

    ResTORbio’s Respiratory Drug Flunks Phase 3 Test, Shattering Shares | Boston

  5. 5.

    Biotech Roundup: Gottlieb v. Juul, Solid Slumps, Avidity Gets $100M & More | National

  6. 6.

    Daré to Add Microchip-Based Birth Control to Women’s Health Portfolio | San Diego

Learn about the Xconomists →

Xconomist Forum

Featured Event

What’s Next in Neuroscience Therapies – Xconomy San Francisco Life Science Forum – Nov. 19, 2019

November 19, 2019

Deal of the Day

$100M

Alkermes/Rodin Therapeutics

People on the Move

With “Inflection Year” Ahead, Ovid Adds Novartis’s Tardio to C-Suite

Equillium Names Chief Business Officer Bruce Steel as Successor CEO

More News

The Feed

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit/Ann Arbor, San Francisco, New York, Raleigh-Durham, Boulder/Denver, Texas, Wisconsin, Indiana, and beyond.

© 2007-2019, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Website development support from Andrew Koyfman with design support from Rob Hunter.